Exact Sciences presented initial data from the NSABP B‑59 sub‑study showing its Oncodetect circulating tumor DNA (ctDNA) MRD test identified triple‑negative breast cancer patients at higher risk of distant recurrence after surgery. Investigators reported that post‑operative MRD positivity correlated with reduced distant recurrence‑free interval, while most MRD‑negative patients remained recurrence‑free at three years. Exact plans to submit data to support Medicare coverage and pursue peer‑reviewed publication. The results add to growing evidence that ctDNA MRD assays can stratify recurrence risk and inform adjuvant decision making in high‑risk breast cancer.